Centogene (CNTG)
(Delayed Data from NSDQ)
$0.42 USD
+0.02 (5.05%)
Updated May 14, 2024 03:54 PM ET
After-Market: $0.44 +0.02 (4.74%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
CNTG 0.42 +0.02(5.05%)
Will CNTG be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CNTG based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CNTG
Patterson Cos. (PDCO) Q4 Earnings and Revenues Top Estimates
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
CNTG: What are Zacks experts saying now?
Zacks Private Portfolio Services
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Lags Revenue Estimates
Tabula Rasa Healthcare (TRHC) Reports Q4 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
Other News for CNTG
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
CENTOGENE and Evotec Unveil Potential Gaucher Disease Treatment
Centogene, Evotec discover new molecule with potential to treat Gaucher disease
Centogene’s Biodatabank Drives Rare Disease Breakthroughs
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients